Efficacy was suggested in one of these studies, in which four patients with NSCLC had a PR as determined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria, two of which had EGFR exon 19 deletions (Yap et al., 2010). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.